The tumour antigens (TAgs) of mammalian polyomaviruses (PyVs) are key proteins responsible for modulating the host cell cycle and are involved in virus replication as well as cell transformation and tumour formation. Here we aimed to identify mRNA sequences of known and novel TAgs encoded by the recently discovered human polyomaviruses 9 and 12 (HPyV9 and HPyV12) in cell culture. Synthetic viral genomes were transfected into human and animal cell lines. Gene expression occurred in most cell lines, as measured by quantitative PCR of cDNA copies of mRNA encoding major structural protein VP1. Large TAg-and small TAg-encoding mRNAs were detected in all cell lines, and additional spliced mRNAs were identified encoding TAg variants of 145 aa (HPyV9) and 84 aa (HPyV12). Using as antigens in ELISA the N-terminal 78 aa common to all respective TAg variants of HPyV9 and HPyV12, seroreactivity of 100 healthy blood donors, 54 patients with malignant diseases of the gastrointestinal tract (GIT) and 32 patients with non-malignant diseases of the GIT was analysed. For comparison, the corresponding TAg N termini of BK PyV (BKPyV) and Merkel cell PyV (MCPyV) were included. Frequent reactivity against HPyV9, HPyV12 and BKPyV TAgs, but not MCPyV TAg, was observed in all tested groups. This indicates expression activity of the early region of three human PyVs in healthy and diseased subjects.
INTRODUCTION
Polyomaviridae represents a taxonomic family of small, non-enveloped viruses with a double-stranded circular DNA of approximately 5 kb. Polyomaviruses (PyVs) have been identified in mammals, birds and recently fish [1] . The typical PyV genome consists of an early region encoding non-structural regulatory proteins, and a late region encoding the structural proteins VP1, VP2 and VP3. The early proteins have regulatory functions, and a small number of mammalian PyVs have been reported to be tumorigenic in their natural host. Although 13 distinct human polyomaviruses have at present been discovered and the oncogenic properties of the human BK polyomavirus (BKPyV), JC polyomavirus (JCPyV) and the Merkel cell polyomavirus (MCPyV) in vitro and in animal models have been documented by numerous reports (reviewed in [2] [3] [4] [5] ), MCPyV is presently the only human virus that seems to be associated with human cancer (Merkel cell carcinoma, MCC) [6] (reviewed in [7] ). BKPyV and JCPyV have also been linked to cancer development but this issue remains controversial and largely unresolved (reviewed in [8] [9] [10] [11] ). A non-human PyV infecting raccoons has been linked to the occurrence of brain tumours [12] , and PyVs infecting hamster, sea lion and African elephant have been isolated from lymphoma, fibropapilloma and fibroma, respectively [13] [14] [15] . In addition, murine PyV (MPyV) [16, 17] , hamster PyV (HaPyV) [18] and simian virus 40 (SV40) [19] induce tumours in laboratory animals under experimental conditions. Large T antigen (LTAg) and small T antigen (STAg) are known to play an essential role in viral transcription and replication [2, [20] [21] [22] . LTAg drives the infected cell into S phase status, the condition for optimal viral replication, and recruits cellular replication factors for promoting viral DNA replication via its helicase domain [22, 23] . PyV infection of permissive host cells is usually lytic and non-transforming. However, infection of non-permissive cells may lead to abortive infection and oncogenic transformation of the infected cell. Both LTAg and STAg play a key role in this transformation process [2, [24] [25] [26] [27] . Besides STAg and LTAg, an increasing number of alternative products of PyV early regions have been identified in the past. The murine MPyV expresses a tiny TAg of 85 aa [28] and SV40 a 17kT TAg of 135 aa [29] . BKPyV encodes a truncated TAg of 136 aa [30] , and JCPyV three alternative TAgs of 135, 136 and 165 aa (named T¢ 135 , T¢ 136 , T¢ 165 ) [31] . MCPyV expresses a 57 kDa TAg (432 aa) and a 28 kDa protein, named ALTO, from non-spliced or spliced mRNA (248 aa/250 aa) [32, 33] . Additional alternative TAgs of 64 kDa (567 aa), 21 kDa (178 aa) and 9 kDa (79 aa) have been detected in a semi-permissive replication system of MCPyV [34] and various truncated LTAgs have been identified in samples of MCC [33, 35, 36] . The human STL polyomavirus encodes a TAg of 229 aa (named 229T) [37] , the human trichodysplasia spinulosa olyomavirus has been reported to encode tiny T (85 aa), middle T (335 aa), 21kT (184 aa) and an ALTO protein (131 aa) [38] , and, most recently, LPyV expresses truncated versions of LTAg and STAg [39] . Few of these alternative TAgs have been reported to exhibit regulatory functions and to play an important role in transforming and immortalizing host cells [29] [30] [31] 40] , while the functions of most alternative TAgs have not been elucidated. Except ALTO, all alternative TAgs have a common N terminus with LTAg and STAg.
In a large body of studies, VP1 has been used as antigen in ELISAs to determine PyV seroresponsiveness and seroprevalence (reviewed in [41] ). In contrast, only few serological data have been reported for LTAg, with seroresponses being less frequent and lower, as compared to VP1. It has been suggested that the host immune system is more readily and even systemically (re)exposed to the viral surface protein VP1, and response to LTAg occurs only in phases of acute infection [42] [43] [44] [45] [46] [47] . Notably, antibodies recognizing MCPyV LTAg have been found specifically associated with MCC cases (22 % positive) compared to population controls (2 % positive), while antibodies recognizing BKPyV LTAg were of low prevalence (2 %) in both groups [45] .
We recently discovered two hitherto unknown human polyomaviruses, human polyomavirus 9 (HPyV9) in the serum of a kidney transplant recipient in 2011 [48] , and human polyomavirus 12 (HPyV12) in metastatic liver tissue of patients with colorectal cancer [49] . Both viruses are circulating in the human population, as seroprevalences of 20-70 % against VP1 of HPyV9 have been readily detected in several studies, and for HPyV12 a VP1-based seroprevalence of 23 % was reported. However, both viruses were generally rarely detected by PCR (reviewed in [50] ). Of note, an HPyV9 genoprevalence of 21 % was recently determined in kidney transplant patients but a pathogenic potential of HPyV9 could not be elucidated [51] . Evidence for an association of HPyV9 and HPyV12 with cancer or other human diseases has so far not been reported [52] .
In the present study, we aimed to determine TAg mRNA sequences formed during HPyV9 and HPyV12 gene expression in vitro, and human seroresponses against their common N terminus. As replicating virus was not available, we transfected synthetic HPyV9 and HPyV12 genomes into various human and animal cell lines. Viral gene expression was monitored by isolation of mRNA and quantitative PCR (qPCR) of cDNA copies of mRNA encoding the major structural protein VP1. LTAg-and STAg-encoding sequences of HPyV9 and HPyV12 were determined on the mRNA level, and for both viruses mRNA was identified that putatively encodes a novel alternative TAg. Seroresponses of healthy human subjects against the common TAg N termini of both viruses were then analysed. As PyV transmission is believed to occur via the gastrointestinal tract (GIT) and, in the case of MCPyV, TAg seroresponse has been shown to reflect tumour burden [45] , we also investigated if a similar specific association of seroresponse against HPyV9 and/or HPyV12 TAgs with malignant diseases of the GIT can be observed. In a pilot case-control study on patients with malignant and non-malignant diseases of the GIT and on healthy subjects, ELISA-based seroresponse against the common TAg N terminus of each virus was observed in all groups.
RESULTS

Analysis of splicing in the early region of HPyV9 and HPyV12
To identify cell lines that allow HPyV9 gene expression, eight cell lines of different cellular origin were tested. As HPyV9 was identified in a kidney transplant patient, four of these were kidney cell lines (Vero, RH, Cos-7, HEK293). In addition, as HPyV9 is closely related to the lymphotropic polyomavirus (LPyV; GenBank accession number K02562), which grows well in BJAB cells (mouse hybridoma cells) [53] , this line was also tested. HeLa (derived from cervical cancer), Huh-7 (hepatocyte-derived cellular carcinoma cell line) and NIH/3T3 cells (derived from mouse embryonic fibroblasts) completed the set. Also for HPyV12 replication, Vero, HeLa, HEK293, NIH/3T3 and RH cells were tested. A375 cells (from human malignant melanoma), A549 cells (from human lung carcinoma) and SW480 cells (from human colon adenocarcinoma) were investigated, because they supported strong HPyV12 promotor activity in recent in vitro experiments [54] . In addition, 293-4 T cells (stably expressing the Merkel cell polyomavirus small T and large T proteins) were included, as they were particularly supportive for replication of Merkel cell polyomavirus [55] . Cells were transfected with circularized genomes using the conditions given in Table S1 (available in the online Supplementary Material), mRNA was isolated at days 0, 1, 3, 6, 9, 13 posttransplantation (p.t.), and cDNA was synthesized. VP1 gene expression was monitored with HPyV9-and HPyV12-specific qPCR of cDNA.
HPyV9 VP1 and HPyV12 VP1 mRNA copies increased in most tested cell lines over time. The highest copy number of HPyV9 VP1 mRNA (n=39 292) was detected in Vero cells at day 3 p.t. Only a minimal increase was seen in 3T3 and HeLa cells. HPyV12 VP1 mRNA was generally much less abundant. The highest copy number of HPyV12 VP1 mRNA (n=2270) was detected in Vero cells at day 6 p.t. In A549, RH and 3T3 cells, HPyV12 VP1 expression was barely detected. In Vero cells, transfection of HPyV12 genomes caused occasional alterations resembling plaque formation, and in HPyV9-transfected Vero cells detachment of rounded cells was infrequently observed (results not shown). Ultrastructural examination of respective sample materials did not reveal virus particles at day 6 p.t., and cell culture supernatants collected at day 6 p.t. were PCR-negative (results not shown).
By analysing the predicted early region of the HPyV9 genome with the Human Splice Finder tool (www.umd.be/ HSF3/index.html; [56] ), potential splice sites resembling canonical splice sequences [57] had been identified for HPyV9 LTAg at positions conserved in related PyVs. These sites flanked an intron of 350 nt [48] (Fig. 1a) . As shown by the agarose gel image in Fig. 2(a 6567as and 6568s/6568as (primer sequences listed in Table 1 ). The product was sequenced by primer walking.
With 2028 nt (primer-binding sites excluded), it covered 99 % of the predicted LTAg coding sequence (CDS) (2048 nt). This confirmed the predicted LTAg intron (Fig. 1b) and respective splice sites ( Table 2 ). The STAg CDS had been predicted as unspliced [48] (Fig. 1a) . This was also confirmed here by LD-PCR analysis of cDNA with the nested primer pairs 6567 and 6568 and sequencing. Of note, the 2201 nt amplification product shown in Fig. 2 (a) displayed directly after the STAg termination codon an intron of 160 nt flanked by canonical splice sites ( Fig. 1b and Table 2 ). Importantly, sequencing of the third and smallest product amplified from cDNA (1886 nt) identified (Figs 1d and 2c) . The other 13 mRNAs revealed one or two introns. The exon/intron borders of the mRNAs with only one intron and the borders of the second intron of the mRNAs with two introns displayed no similarity to canonical splice sites. The biological relevance of these 13 sequences remains unclear (data not shown). Since the amplification of these products hampered amplification of complete LTAg coding sequence on the mRNA level, PCR was performed that targets the 5¢ part (approximately 1 kb) of the early region, using the primers 6577s/5698as ( Table 1 ). The antisense primer was placed in a region where all identified mRNAs displayed an intron. Sequences in line with the predicted LTAg CDS were detected in HEK-293, Vero, HeLa, A375 and A549 cells (Fig. 1d) . Finally, neither spliced nor unspliced mRNA was detected that encodes the predicted STAg. (Fig. 3a) , synthesized, expressed in Escherichia coli K12 and purified as described previously [58] . Sera of n=54 patients with malignant diseases (MD) of the GIT, n=32 patients with non-malignant diseases (NMD) of the GIT, and a sex-and age-matched control group of n=100 healthy blood donors (BD) were tested with ELISA for reactivity against the purified TAg sequences as described in the Methods. Fig. 3b and Table 3 ). The respective absorbance values at 450 nm are shown as box-and-whisker plots in Fig. S1 . For HPyV9, HPyV12 and BKPyV, the differences between the three groups were not significant (except weak significance for HPyV12, BD vs MD; P=0.04). A significant difference in seroprevalence between males and females was not observed (data not shown ( 
DISCUSSION
In the present study, we analysed HPyV9 and HPyV12 mRNA formation after transfection of synthetic circularized HPyV9 and HPyV12 genomes into several human and animal cell lines. As the natural host cells of these viruses are presently unknown, the cell lines could not be specifically selected, and only a moderate level of viral gene expression was observed in a number of the tested lines. In the first line, this was indicated by an increase of VP1 transcripts as measured by qPCR. The increase was most marked in Vero cells and approximately 10-fold higher for HPyV9 than for HPyV12. The occasional cellular alterations observed in HPyV9 and HPyV12 transfected cells may indicate virus replication at low level. However, it may have also been due to a genotoxic effect of expressed TAgs. As detection of viral particles by electron microscopy was unsuccessful and supernatants of transfected cells did not display viral progeny, as indicated by the absence of PCR-detectable viral DNA, it is concluded that virus replication and particle formation (i) were absent or (ii) occurred at a very low level. This failure to produce viral progeny in sufficient amounts is not surprising as PyV replication and particle formation are usually highly restricted to only a few cell types, and for the majority of human polyomaviruses [KIPyV, WUPyV, HPyV6, HPyV7, TSPyV, MWPyV, STLPyV (taxonomic designations: Human polyomavirus 3, 4, 6, 7, 8, 10, 11 [59] )] tissue culture systems are lacking. Of note, transfection of recircularized viral DNA of HPyV9-UF1, a variant isolated from peripheral monocytes of an AIDS patient, into Namalwa (Burkitt's lymphoma) and BJAB (B lymphoma) cells did not produce viral progeny [60] .
Despite the semi-permissiveness of our in vitro system, it served as a suitable basis for detection of spliced mRNAs transcribed from the early regions of both HPyV9 and -12. For HPyV9, the near complete LTAg CDS could be verified in all cell lines tested (n=7), with intron and flanking splice sites as predicted. For the STAg-encoding mRNA, an intron was identified in all cell lines that immediately follows the termination codon (Fig. 1b) . These findings are completely in line with the LTAg and STAg annotations for the closely related LPyV that are also based on experimental analysis in cell culture [39] . Comparison of the HPyV9 and LPyV genome sequences with those of the phylogenetically related PyVs infecting western chimpanzee (accession no. JX159982), eastern chimpanzee (JX159983), crab-eating macaque (JX159986), vervet monkey (AB767297) and yellow baboon (AB767294) revealed that the splice donor and acceptor sites of LTAg mRNA are identical and occupy conserved positions (Fig. 4) . The same holds true for the splice sites flanking the intron in STAg mRNA. In addition, while the splice donor site flanking the intron of the novel HPyV9 145T CDS is identical with the conserved donor site of the LTAg intron, the 145T splice acceptor site is positioned downstream of the LTAg acceptor site. Remarkably, it is identical to the acceptor site of the HPyV9 STAg intron, lies in the early-region alignment shown in Fig. 4 at a conserved position and displays high similarity among the viruses. Similarly, the splice sites of the LPyV transcripts LTAg¢ and STAg¢ [39] are obviously conserved in the majority of the HPyV9-related virus genomes (Fig. 4) . Neither LTAg¢ nor STAg¢ has been detected in our experiments with HPyV9, and a 145T equivalent was not detected by Gupta and colleagues [39] . This is probably due to very different abundances of the TAg variant-encoding mRNAs (as shown for, for example, MCPyV LTAg variant mRNAs [34] ), depending on virus, cell line, sampling time p.t. and the respective TAg variant. In addition, mRNAs with large introns result in shorter PCR products, as compared to mRNAs with short introns. Therefore, amplification of the former may interfere with that of the latter. Taken together, experimental and bioinformatic analysis revealed that splicing in the HPyV9-related PyV group occurs by use of evolutionarily conserved splice sites.
PCR amplification of the early region of HPyV12 from cDNA of transfected cell lines revealed the predicted LTAg intron plus about one-third of the LTAg CDS in six of nine cell lines. Amplification of the full LTAg CDS was probably hampered by that of several shorter CDS, such as the 84T CDS. Unspliced or spliced STAg mRNA could also not be identified, the underlying reason probably being the same as mentioned above for HPyV9. Remarkably, a plethora of mRNAs were amplified that contained introns with (partially or fully) non-canonical splice sites. It is unknown by which mechanism they arose and what their function is, or if they were mere artefacts without any functional relevance. An argument against the latter is that five of these mRNAs were detected in 2-4 cell lines and at different time points. Furthermore, those mRNAs with two introns had canonical splice sites flanking the first intron. Only the sites flanking the second introns did not reveal canonical motifs or any common patterns. Further studies are required to elucidate their relevance, as well as to unravel the function of HPyV9 145T and HPyV12 84T in the PyV life cycle.
Seroreactivities were frequently observed using the 78 aa N terminus common to all respective TAg variants of either HPyV9, HPyV12 or BKPyV as antigen in ELISA. In contrast, no reactivities were observed against the 78 aa N terminus common to all respective TAg variants of either MCPyV or a bird PyV (BFDPyV). Concerning BKPyV, this is in disagreement with previous studies on BKPyV LTAg that reported <1 to 2.1 % seroreactivity [45, 61, 62] . However, a more marked seroreactivity against BKPyV LTAg was observed in testing sera of 33 patients with systemic lupus erythematosus (54 %), 32 patients with rheumatoid arthritis/Sjögren's syndrome (34 %) and 27 randomly selected patients with auto-immune diseases (33 %) [63] . The seroreactivities of 43-57 % observed for BKPyV in the present study may have been more pronounced because the N terminus common to all TAgs was used and not complete LTAg. The use of the N terminus ensures that not only LTAg is detected, but also STAg and other TAg variants, as in the case of BKPyV truncated TAg [30] . When complete LTAg is used in ELISA, only about 10 % of the complete antigen reacts also with antibodies against STAg or alternative (truncated) TAgs.
In the present study, no ELISA seroreactivity was detected against the N terminus of MCPyV TAgs in n=100 healthy subjects and n=86 patients with diseases of the GIT. This is largely in accordance with Paulson et al., who detected 1.7 and 0.9 % seroreactivity against MCPyV LTAg and STAg, respectively, in 520 non-MCC patients [45] .
Frequencies of ELISA reactivity against TAg of HPyV9 and HPyV12 were comparable to those against BKPyV (Fig. 3b) . Although the five PyVs analysed here share a highly conserved DNAJ motif of 6 aa in their TAg N terminus (Fig. 3a) , it can be excluded that the ELISA reactions against HPyV9, HPyV12 and BKPyV TAgs resulted from serological cross-reactions targeting the conserved motif, as the same motif is present in TAgs of the ELISA-negative MCPyV and BFDPyV (Fig. 3a) , and the OD values of HPyV9, HPyV12 and BKPyV TAG ELISA did not correlate. Taken together, the serological data probably indicate activity of the early region of three human PyVs (HPyV9, HPyV12, BKPyV) in healthy subjects and patients with GIT diseases.
In conclusion, these first studies on gene expression of HPyV9 and HPyV12 in vitro resulted in the identification of spliced transcripts encoding LTAg, STAg and alternative, truncated TAgs. Seroresponses against the TAgs of both viruses were observed in healthy human subjects and patients with diseases of the GIT. In future studies, attempts will be made to identify the natural host cells of HPyV9 and HPyV12 and thus allow the development of more efficient replication systems. This may also help to identify the presently elusive pathogenic properties of both viruses.
METHODS
Polyomavirus genomes
Genomes of HPyV9 (HQ696595; [48] ) and HPyV12 (JX308829; [49] ) were commercially synthesized and delivered inserted into a plasmid (MrGene and Biomatik, respectively). For transfection, the genomes were excised from the plasmid and re-ligated. 
Cell lines
Transfection of cells
For transfection of cells with PyV genomes, the reagents X-treme GENE (Roche Applied Biosciences) and GeneJuice (Novagen/Merck) were used. Transfection parameters were optimized for each cell line and listed in Table S1 . Cells were seeded in a volume of 500 µl cell culture medium in tissue culture plates with 24 wells (Nunc). Transfection procedures were performed approximately 20 h after seeding according to the manufacturer's instructions.
RNA extraction and PCR methods RNA was isolated on days 0, 1, 3, 6, 9 and 13 p.t. using the Macherey-Nagel Total RNA Isolation kit according to the manufacturer's instructions. DNA was removed by an additional Turbo DNA-free DNase treatment (Ambion). RNA concentrations were determined with a NanoDrop 8000 device (ThermoScientific) at 260 nm. Synthesis of cDNA was carried out with 500 ng RNA using SuperScript II Reverse Transcriptase (Invitrogen) and oligo(dT) 16 primers (Roche Applied Bioscience).
qPCR (TaqMan), with primers and probe specific for HPyV9 and HPyV12 VP1, respectively, was performed essentially as described before [49, 58] . Expression of recombinant TAg proteins, ELISA and statistical analysis Nucleic acid sequences that encode the N-terminal 78 aa of HPyV9, HPyV12, BKPyV, MCPyV and BFDPyV LTAgs were codon-optimized and commercially synthesized (GeneArt; Life Technologies). The expression and purification of His-tagged proteins, and ELISA protocol were essentially as described previously for PyV VP1 proteins [58] . The cut-off value (COV) for the ELISA was determined experimentally. The background reactivities detected in wells without antigen coating and those without both antigen and serum (blanks) were subtracted from the ODs measured in VP1-coated wells. The COV defining a positive serological response was defined as the mean of all negative OD values plus standard deviation [58] . To ensure that the final A 450 values measured for HPyV9, HPyV12, BKPyV and MCPyV TAgs were not derived in part from antibodies to epitopes conserved among the PyVs or resulting from antibodies non-specific for PyVs, the reactivity of the sera to the LTAg N terminus of the avian PyV BFDPyV was measured (mean A 450 =0.07), and the values obtained for each serum sample were subtracted from the A 450 values measured for HPyV9, HPyV12, MCPyV and BKPyV LTAgs. This was essentially as done before for reactivity of human sera against HPyV12 VP1 [49] . The data were analysed with a t-test to estimate the significance of differences among independent groups of individuals.
Collection of sera and ethics statement
In total, 54 patients with malignant diseases of the GIT (Table 2 ) and n=32 patients with non-malignant diseases of the GIT (Table 2) were included in the study. Sera were collected after surgical intervention. The study protocol for collection of serum samples was in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration and approved by the local ethics committee (application number EA2/ 144/11). Written informed consent was obtained from all patients. In addition, retained samples from anonymized blood donors collected after the retention period were used in this study. They were taken from a panel that had already been studied previously for polyomavirus seroprevalence [49, 58] .
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